Click HERE to register.

Join Amit Singal, MD, MS, Anthony El-Khoueiry, MD, Robin K. (“Katie”) Kelley, MD, and Riad Salem, MD, MBA for this PeerView MasterClass and Tumor Board program that will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each Tumor Board discussion will feature reflective case-centered discussion on the increasingly important role that hepatology professionals play for patients across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients!

Join Us for One of Two Web Broadcasts

• Friday, November 13, 2020: 7:00–8:30 PM EST
• Tuesday, December 1, 2020: 7:00–8:30 PM EST

Activity Description

The management of hepatocellular carcinoma (HCC) is in the midst of a therapeutic paradigm shift. Partial hepatectomy, liver transplantation, ablation, radiation therapy, and embolization procedures remain important interventions for localized HCC, whereas sorafenib, a multikinase inhibitor, was for a decade the cornerstone of therapy for patients with extrahepatic disease. Recently, several immunotherapies and targeted therapies, used as single agents or as part of combinations, have been approved and validated for treating patients with advanced HCC. Moreover, emerging data and ongoing trials indicate that therapeutic advances for this malignancy are increasingly centered around exploiting the benefits of combination regimens with immunotherapy, as well as investigating innovative strategies such as adjuvant immunotherapy, tumor treating fields, and combinations of systemic agents with locoregional therapies.

Target Audience

This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, oncologists, interventional radiologists, and other healthcare professionals involved in the care of patients with HCC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the key clinical evidence on available systemic treatments, including multikinase, immune checkpoint, and antiangiogenic inhibitors, for advanced HCC
• Assess available and emerging combination strategies, such as targeted therapies with immunotherapy, dual checkpoint inhibition, and systemic agents with locoregional modalities across the disease spectrum of HCC
• Develop personalized therapeutic plans in the first and subsequent lines of treatment for patients with advanced HCC
• Incorporate multidisciplinary care approaches for the optimal management of patients with HCC, including those along the intermediate to advanced stage disease continuum

Faculty

Chair & Presenter

Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas

Presenters

Anthony El-Khoueiry, MD
USC Norris Comprehensive Cancer Center
Los Angeles, California

Robin K. (“Katie”) Kelley, MD
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Accreditation

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™.